For the past couple weeks I’ve been writing on this blog and in our newsletter about FDA drug approval dates (PDUFA dates) and the impact that these catalysts can have on a drug manufacturer’s stock price. This week I thought I would let our partner Informa do most of the talking. And why not, considering their opinions successfully predicted 75% of the catalyst outcomes that occurred in Q4 2015!
Click HERE for Informa’s Early 2016 Outlook Report that highlights the impact of several significant catalyst events from Q4 2015 and includes details and opinions on twenty-two (22) upcoming drug and device/diagnostic events expected to occur in early 2016. In addition, there is an extensive listing of large impact catalysts in the drug and device/diagnostic areas through early 2016. Enjoy!